Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Febuxostat × Clear all

Phase

Status

Completed 2 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1 Hematologic Neoplasms 1

Interventions

Cyclophosphamide 387 Carboplatin 337 Gemcitabine 328 pembrolizumab 323 Cisplatin 323 Radiotherapy 295 Paclitaxel 294 Docetaxel 283 Bevacizumab 250 Rituximab 233 Capecitabine 222 Nivolumab 215 Dexamethasone 202 Fluorouracil 188 fludarabine 175 Oxaliplatin 175 Doxorubicin 153 Pemetrexed 148 Irinotecan 148 Leucovorin 142 Etoposide 142 Cytarabine 131 Bortezomib 128 fludarabine phosphate 126 Cetuximab 126 Lenalidomide 123 Erlotinib Hydrochloride 120 Filgrastim 119 Temozolomide 113 Radiosurgery 111

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03605212 2021-06-03

FLORET

Menarini Group

Phase 1/2 Terminated

30 enrolled 14 charts

Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡